Payment overview · 2025
General Payments
$75.47
4 reported records · 3 companies
Healthcare provider profile · identity verified
Jack A Maxwell, DO
Allopathic & Osteopathic Physicians|Family Medicine · HICKORY CREEK, TX · NPI 1679585087
Verified facts
What the public records show
CMS Open Payments records show Jack A Maxwell, DO received $75.47 in general payments during 2025 across 4 reported records.
Novo Nordisk Inc accounted for 51.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.53 | 51.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.92 | 27.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.02 | 21.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $75.47 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $38.53 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $38.53 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.92 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.92 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $16.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 54 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
50 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
54 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 368 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 289 | 103 |
| Lisinopril | Lisinopril | 281 | 100 |
| Amlodipine Besylate | Amlodipine Besylate | 275 | 94 |
| Losartan Potassium | Losartan Potassium | 275 | 89 |
| Omeprazole | Omeprazole | 223 | 75 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 212 | 84 |
| Hydrochlorothiazide | Hydrochlorothiazide | 194 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 159 | 59 |
| Metformin Hcl | Metformin Hcl | 156 | 54 |
| Sertraline Hcl | Sertraline Hcl | 150 | 50 |
| Meloxicam | Meloxicam | 137 | 53 |
| Simvastatin | Simvastatin | 135 | 43 |
| Trazodone Hcl | Trazodone Hcl | 127 | 41 |
| Gabapentin | Gabapentin | 123 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 116 | 40 |
| Alprazolam | Alprazolam | 115 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 115 | 44 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 105 | 38 |
| Carvedilol | Carvedilol | 103 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 101 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 93 | 30 |
| Glimepiride | Glimepiride | 90 | 28 |
| Allopurinol | Allopurinol | 89 | 33 |
| Tramadol Hcl | Tramadol Hcl | 86 | 27 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 83 | 27 |
| Alendronate Sodium | Alendronate Sodium | 81 | 16 |
| Bupropion Xl | Bupropion Hcl | 81 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 79 | 24 |
| Furosemide | Furosemide | 78 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 25 |
| Finasteride | Finasteride | 72 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 23 |
| Montelukast Sodium | Montelukast Sodium | 71 | 29 |
| Clonazepam | Clonazepam | 67 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 25 |
| Metformin Hcl Er | Metformin Hcl | 64 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 31 |
| Ezetimibe | Ezetimibe | 58 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 56 | 23 |
| Celecoxib | Celecoxib | 54 | 20 |
| Ozempic | Semaglutide | 54 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 51 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 50 | 12 |
| Fenofibrate | Fenofibrate | 48 | 17 |
| Potassium Chloride | Potassium Chloride | 48 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 42 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 41 | 12 |
| Pregabalin | Pregabalin | 38 | 12 |
| Estradiol | Estradiol | 37 | 14 |
| Synthroid | Levothyroxine Sodium | 37 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Eliquis | Apixaban | 30 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 28 | 11 |
| Prednisone | Prednisone | 28 | 21 |
| Valsartan | Valsartan | 28 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 18 |
| Cephalexin | Cephalexin | 20 | 15 |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Famotidine | Famotidine | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Spironolactone | Spironolactone | 15 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Etodolac | Etodolac | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $75.47 · 4 records | Novo Nordisk Inc | AREXVY, Ozempic, Rybelsus, SHINGRIX, VYEPTI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error